ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a biopharmaceutical business engaged in advancing novel RNA interference therapeutics and discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.

$3.70  -0.45 (-10.84%)
As of 12/06/2021 15:14:10 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Canada
Country of incorporation:  Canada
IPO date:  11/15/2010
Outstanding shares:  135,269,247
Average volume:  22,772,008
Market cap:   $583,010,455
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    03879J100
ISIN:        CA03879J1003
Sedol:      BZ0QMB7
Valuation   (See tab for details)
PE ratio:   -6.48
PB ratio:   3.23
PS ratio:   57.34
Return on equity:   -55.30%
Net income %:   -707.79%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy